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 Optimal Designs for Evaluating a Series of Treatments
 Denis Heng-Yan Leung
 Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center,




 Department of Biostatistics, Harvard School of Public Health,
 655 Huntington Avenue, Boston, Massachusetts 02115, U.S.A.
 email: ygwang~hsph.harvard.edu
 SUMMARY. Several articles in this journal have studied optimal designs for testing a series of treatments
 to identify promising ones for further study. These designs formulate testing as an ongoing process until
 a promising treatment is identified. This formulation is considered to be more realistic but substantially
 increases the computational complexity. In this article, we show that these new designs, which control the
 error rates for a series of treatments, can be reformulated as conventional designs that control the error
 rates for each individual treatment. This reformulation leads to a more meaningful interpretation of the
 error rates and hence easier specification of the error rates in practice. The reformulation also allows us to
 use conventional designs from published tables or standard computer programs to design trials for a series
 of treatments. We illustrate these using a study in soft tissue sarcoma.
 KEY WORDS: Bayesian; Optimality; Phase I studies; Screening; Sequential trials; Soft tissue sarcoma.
 1. Introduction
 A number of research programs at Memorial Sloan-Kettering
 Cancer Center (MSKCC) have prompted the need to test a
 series of treatments to identify promising ones for more in-
 tensive studies. One example is in the Immunology Program,
 where a large number of vaccines are to be screened for po-
 tentially efficacious ones for further study. Another example is
 in the Soft Tissue Sarcoma Chemotherapy Program, where a
 large number of Phase II trials are to be implemented for iden-
 tifying promising chemotherapy agents. In response to these
 needs, a number of design strategies have recently been pro-
 posed (Yao, Begg, and Livingston, 1996; Wang and Leung,
 1998; Yao and Venkatraman, 1998). A novel aspect in these
 designs is the recognition that it is not possible to predict
 when a promising treatment will appear and therefore no up-
 per limit is placed on the number of treatments to test in these
 designs. The goal is to find the first promising treatment with
 the smallest expected number of patients while the errors of
 falsely accepting a nonpromising treatment and of rejecting
 one or more promising treatments are controlled for.
 Yao et al. (1996) (referred to as YBL hereafter) used a
 single-stage design to solve this problem. That is, n patients
 are to be tested on each treatment and a treatment will be ac-
 cepted or rejected depending on whether >k or <k successes
 are seen. More recently, Yao and Venkatraman (1998) (here-
 after called YV) considered a two-stage design after YBL.
 The design consists of a series of two-stage trials. The max-
 imum sample size in the two stages are ni and n2, respec-
 tively. If k1 or fewer successes at the end of the first stage
 or a total of k2 or fewer successes at the end of the second
 stage are observed, the treatment will be rejected. They fur-
 ther suggested a truncated two-stage design. For example,
 if (kl, ni, k2, n2) are the parameters, then we need not test
 the treatment any further as soon as ni - k1 failures are ob-
 served because this treatment will definitely be rejected even
 if we finish the first-stage testing. Similarly, the design can be
 truncated at n2 + ni - k2 failures in the second stage. There-
 fore, they suggested stopping testing as soon as these events
 have been observed. Hence, they have changed their two-stage
 monitoring to fully sequential monitoring except the stopping
 boundaries remained defined by an optimal two-stage design.
 In fact, the optimal fully sequential design is given by Wang
 and Leung (1998) (hereafter called WL), in which the two
 types of error rates are achieved by using Lagrangian con-
 straints.
 Although it is more realistic to consider testing a series of
 treatments as an ongoing process, this approach adds sub-
 stantial conceptual complexity to the design problem. In this
 article, we show that the design for testing a series of treat-
 ments is merely a series of identical designs for testing the
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 individual treatments. The design for individual treatments
 can be one of the conventional designs (one stage, two stage,
 multistage) in the literature. We will establish a link between
 the error rates in the conventional design and the error rates
 in the design for the ongoing process. This link will allow us to
 convert the error rates for different designs. We identify two
 uses of our work. First, we show in Sections 2 and 3 that the
 error rates for the individual treatments are easier to interpret
 and hence easier to specify in practice. When designing tri-
 als involving a series of treatments, we suggest specifying the
 error rates for the individual treatments. As long as the con-
 verted error rates are used in the conventional design for the
 individual treatments, the overall errors for testing a series
 of treatments will be maintained at the desired level. Second,
 the design problem for a series of treatments can be solved
 using conventional designs, which are easily available from
 published tables or from standard computer programs. We
 illustrate these uses in an example in soft tissue sarcoma.
 2. Ongoing Process Versus Single Treatment
 The problem of testing or screening a series of treatments can
 be written formally as follows. Suppose the success proba-
 bility of the ith selected treatment is Oi and a treatment is
 considered to be promising if Oi > 0*. The trial consists of a
 series of testing of
 Ho: Oi < 0* versus H1: Oi > 0*.
 In general, 0i is unknown but we may impose a prior distribu-
 tion on 0i to reflect our knowledge about the treatments. In
 practice, it is impossible to predict how many treatments to
 test before a promising one can be identified. Therefore, we as-
 sume that there is an indefinite series of treatments available
 and that a rejected treatment will never be tested again, so
 after a rejection, the screening problem returns to its original
 state (see YBL, YV, and WL). This assumption is important
 because the order in which a treatment arrives becomes ir-
 relevant and so the same testing strategy can be used for all
 treatments in the screening trial.
 For any particular design used in the screening process,
 two types of errors can be identified, (1) that of accepting a
 nonpromising treatment (al) and (2) that of rejecting one or
 more promising ones (a2). If we denote the testing outcome
 for a treatment as Y (0 = rejected and 1 = accepted), then
 the two error rates can be expressed as (see YBL)
 a1 =Pr(0i <0* IY= 1}= P+- _
 a2 = P +, l
 where
 p__ = Pr(Y = 0, Oi < 0*),
 p-+ =Pr(Y =-0,Oi> 0*),
 p+_= Pr(Y =l,O i<0*),
 p++ = Pr(Y = 1,Oi > 0*).
 The design problem is to minimize the expected overall num-
 ber of patients to find the first promising treatment when
 al and a2 are controlled. Note that al and a2 are posterior
 probabilities and are different from traditional Type I and II
 errors.
 By considering the screening trial as an ongoing hypothe-
 sis testing problem, each treatment is considered to have the
 same response distribution in the design for the ongoing pro-
 cess. Therefore, the same design can be used for all treatments
 in the trial. However, the ongoing process still adds consid-
 erable complexities to the determination and interpretation
 of the design. Here we show that the ongoing process is inti-
 mately linked to the tests of the individual treatments.
 2.1 Error Rates
 From (1), it is clear that the four quantities (p p+, p_+,
 p++) are determined entirely by the errors (a1, a2) together
 with the two constraints: p++ + p-+ = Pr(0 > 0*) and
 p++ + p+- + p-+ + p__ = 1. The value Pr(Oi > 0*) will
 be denoted as p for convenience.
 Now consider the error rates for any particular treatment
 rather than the overall error rate of the screening process. The
 false-positive error, al, is unaffected but the false-negative
 error is the probability that a rejected treatment is in fact a
 promising one, i.e.,
 a* = Pr(0i > 0* Y = 0}= P-+
 2 ~~~~p-+ +p--
 From (1), we can obtain the relationship between a2 and
 a2 as
 * R2P .'2
 a a2P ~~~~~~~~~~(2) 2 a1- 2)(al +P)'
 Consequently, if one is interested in an optimal design for
 the screening trial with error rates (al , aL2), one simply needs
 to find the optimal design for a single treatment trial with
 error rates (ai, a*). This conventional design for a single
 treatment trial with error rates (a1, a*) is also the optimal
 design for the ongoing process with error rates (a 1, a2)- Some
 values of c2 and a* for various values of p and al = 0.1
 are given in Table 1. We note that, from Table 1, a2 is in
 general larger than a*. But this is not true when p is large,
 as it results in a large probability of acceptance each time
 (i.e., when the expected number of treatments needed to test
 before a promising one can be found is small).
 Because the screening of new treatments is modeled as
 an ongoing process, the use of a2 is appealing. However,
 Table 1
 Values of a2, a* for different
 values of p Pr(0 > 0*), al = 0.1
 P a2 2
 0.100 0.050 0.006
 0.300 0.050 0.024
 0.500 0.050 0.058
 0.100 0.150 0.018
 0.300 0.150 0.068
 0.500 0.150 0.153
 0.100 0.250 0.029
 0.300 0.250 0.107
 0.500 0.250 0.227
 0.100 0.350 0.040
 0.300 0.350 0.142
 0.500 0.350 0.287
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 (2 is defined in terms of the expected number of rejected
 treatments before a promising one is declared. This limits
 its practical use in two ways. First, it cannot be used to
 make statements about the false-error rate among rejected
 treatments in any particular trial because the number of
 rejected treatments is a random number. Second, its interpre-
 tation is only meaningful if the expected number of rejected
 treatments is also reported. Therefore, we suggest specifying
 a* instead. The interpretation of a* is clear; it is simply the
 probability of a false negative when a treatment is rejected.
 Because of (2), the use of a* will also control the overall error
 of the trial to be bounded by (2. If we choose to control
 ((:x, a*), the design would have (p++,p+-) given by
 (- l)(P- a2)
 a- 1-e- a*'
 From a Bayesian viewpoint, (1 - alac*) are the two
 posterior probabilities of being promising when the treatment
 is accepted or rejected. Note that the prior probability of
 being promising is p. Therefore, (1 - al)/p measures the
 efficiency of screening and a* /p can be interpreted as the
 remaining efficiency among those rejected. Other variations of
 the error probabilities may be used depending on the context
 of the trials. Or alternatively, one can just specify the desired
 proportions p++ and p+-, and a variety of error probabilities
 can then be evaluated. As we mentioned, the error rates are
 all essentially determined by p++ and p+-.
 2.2 Sample Size
 If E(T) is the expected sample size for each treatment to be
 tested, the expected sample size until a promising treatment
 is identified is N = E(T)Nv, where N, is the expected
 number of treatments to be tested before a promising one
 is accepted. For any given error probabilities ((:x,(:x2), the
 expected number of trials required to identify a promising
 one is
 N 1-= I (1 - a2)
 (1- a2)P
 The design aims to minimize the expected sample size,
 N, until a promising treatment is identified. In fact, given
 two error probabilities, (al, a:2) or (ai, :x), or any other
 variations (functions of p++ and p+-), Nv is a constant
 for any design, i.e., Nv = [1 - al(1 - a2)]/[(1 - a2)P].
 So an optimal design can be obtained by minimizing the
 expected sample size for testing each treatment, E(T), with
 controlled error rates ((xi,(:x). Therefore, treating screening
 as an ongoing process does not change any essential aspects
 of the design, i.e., a design that is optimal for each individual
 treatment is also optimal for the overall ongoing process (until
 a promising one is identified) and vice versa.
 2.3 Connection to Conventional Designs Under a
 Two-Point Prior
 So far, we have formulated the hypothesis testing problem as a
 test of Ho: Oi > 0* versus H1: Oi > 0*. But often, we simplify
 the problem to that of testing Ho: 0i = So < 0* against
 H': Oi = Oa > 0*. In that case, we can assume a two-point
 prior for the success probability O- so that Pr(02 =o) 1-p
 and Pr(Oj = Oa) = p. Let
 a = Pr(Y = I I Oi -00); ,3 = Pr(Y = 0 l Oi = Oa)
 be the frequentist Type I and II error rates. Then one can
 show (cf., Lee and Zelen, 2000) that ar and ,3 can be obtained
 from al and a* using the following relationships:
 al1(P-ca*)
 (I1-p)(I l- - a*)
 c*(1 - at1 - P)
 2 ~~~~~~~~~(3) p(l - a - a*)'
 Therefore, to design a trial for testing a series of treatments,
 with errors (a1,ac2), we first use (2) to convert (a1,ac2) to
 (al, a*). Then we use (3) to convert (ael, a*) to the frequentist
 errors (oe,3). Based on (ae,,l3), the optimal design for a series
 of treatments can be easily obtained from standard tables or
 programs.
 3. Soft Tissue Sarcoma Trials
 Every year, MSKCC conducts a large variety of clinical
 trials on treatments for different types of malignancies.
 Among these are the trials in the chemotherapy program for
 soft tissue sarcomas (NIH grant PO1-47179). The primary
 goal of this program is to identify promising chemotherapy
 treatments, through a series of Phase I and II trials, for further
 study. A total of 12 different Phase II trials are planned for
 the next 5 years. We illustrate the implications of the issues
 raised in Section 2 in this context.
 We used prior knowledge from 52 historical Phase II trial
 results (Yang et al., 1993) to help us in designing the new trials
 in the program. We acknowledged that there is a possibility
 of publication bias, which will be ignored in this illustration.
 The 52 historical trials arise from 30 different combination
 chemotherapy treatments. The number of patients used on
 these combination treatments ranges from 8 to 732. In
 forming the prior, we included only studies with doxorubicin-,
 epirubicin-, and ifosfamide-based treatments because the new
 treatments to be tested are either combinations based on
 one of these three or with similar activities to these three.
 The efficacy of each treatment is measured in terms of the
 percent of complete response, which is defined as complete
 disappearance of the tumor. We assumed that each treatment
 has a probability of complete response that follows a beta
 distribution. We found the best fitting beta-binomial model
 to these data to be beta(1.3, 8.6).
 Our clinical collaborators have indicated that only
 treatments with a complete response rate of >20% are worthy
 of further investigation. Under the prior, the proportion
 of treatments worthy of further study is 0.217. We limit
 the false-positive error (ael) to be under 10% and false-
 negative error (ac2) to be under 30%. YV's optimal design,
 when restricting N = ni + n2 < 100, is (k,rnl, k2,rn2) =
 (2,17,16,56). The average number of patients required to find
 a promising treatment using this design is 225.5. Using WL's
 fully sequential design and constraining the maximum sample
 size of each Phase II trial to be the same as YV's design, the
 optimal design requires, on average, 145.2 patients to reach a
 promising treatment. Therefore, the savings by adopting the
 fully sequential design over a two-stage design is about 35%.
 The fully sequential design reduces patient numbers by having
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 the opportunity to stop earlier. Note that the sample size per
 Phase II trial is quite large in order to control for moderate
 values of al and a2. However, from (2), we can obtain a* to
 be 0.084 only. In other words, when a treatment is rejected,
 the probability that it has a response rate of >20% is 8.4%.
 Therefore, the design controls (al, a*) to be under 10% each
 even though a2 is 30%.
 Using a1 = 0.1 and c2 = 0.3, the average number
 of treatments to test before a positive one is declared is
 (NV - 1) = 5.2. This number is a constant for the design, with
 (a1, a2) = (0.1,0.3) or, equivalently, (a,, a*) = (0.1,0.084).
 The interpretation of al is clear; it is the probability of
 a false-positive error. However, the interpretation of a2 is
 not as straightforward. Suppose, in a particular trial, we
 rejected four treatments before accepting a promising one.
 Then, even though we know a2 = 0.3, we cannot use it to
 make statements about the chance of false-negative errors
 in any of the four rejected treatments. On the other hand,
 using a* = 0.084, we know the chance of a false negative for
 each rejected treatment is 8.4% in each of the four rejected
 treatments.
 A second problem in interpreting a2 is as follows. The
 quantity a2 = 0.3 refers to the probability that at least one of
 the rejected treatments is promising and is equal to 0.3. This
 probability is based on an average of 5.2 rejected treatments
 (i.e., N -I = 5.2). If we keep a2 = 0.3 but specify al to be
 0.2, then (NV - 1) becomes 4.7. In this case, even though a2
 is still 0.3, it is now based on an average of only 4.7 rejected
 treatments, which is more serious than when it is based on an
 average of 5.2 rejected treatments. Therefore, two identical
 specifications of a2 represent two different levels of errors
 committed. The interpretation of a2 depends on NV, which in
 turn depends on (a1, a2), and the observed NV value follows
 a geometric distribution. This makes it difficult to specify the
 error rates in terms of (ael, ar2) in practice. On the other hand,
 the meaning of a* is unchanged, as its interpretation is for
 individual treatments rather than for a series of treatments.
 When al changes to 0.2 from 0.1 while fixing a2 at 0.3, a2
 changes to 0.091 from 0.084.
 Finally, we illustrate how the design problem for a series of
 trials can be simplified when one assumes a two-point prior
 for Oi. Based on the data, we assume that we are interested in
 testing Oi 0.1 versus Oi = 0.3 and Pr(0i = 0.1) = 0.7
 and Pr(i= 0.3) = 0.3. Furthermore, suppose we allow
 errors of al - 0.1 and a2 = 0.1. For ease of illustration, we
 use the one-stage design of YBL. Then using (2), we obtain
 a* = 0.042. From (3), we then have (a,:3) = (0.043,0.098).
 Using standard programs from standard single-treatment
 trials, with (ae,,/3) = (0.043,0.098), we obtain the optimal
 one-stage design as in YBL (Table 1). This design is given
 by (n, k) = (33, 6) and it means to use 33 patients for each
 treatment and then declare the treatment as promising if more
 than six successful responses are observed.
 4. Discussion
 In this article, we established a link between the overall
 error probability for the ongoing process framework and the
 errors for each individual treatment. Error probabilities in
 terms of the individual treatments may be more meaningful
 in practice. This concept was also suggested in a recent
 discussion paper by Lee and Zelen (2000) in a different
 context. The interpretation of these error rates is also easier.
 For example, if (cei, ?c2) are controlled at (0.1, 0.05), we would
 expect 90% of those accepted for further study are truly
 promising and only 5% among those rejected are promising.
 On the other hand, a2 is the probability of rejecting
 one or more promising treatments before we recommend
 a promising one. But since the number of treatments
 test d before recommending a promising one is a random
 variable (geometrically distributed with a mean of Nb),
 the interpretation of a2 is awkward. We therefore believe
 specifying a* is more meaningful in practice. Furthermore,
 when the prior is a two-point prior, standard programs or
 published tables can be used to obtain optimal designs with
 specified (a1,ac*) values.
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 RESUME
 Plusieurs articles, dans cette revue, ont etudie des plans
 optimaux permettant de tester differents traitements-
 les uns a la suite des autres dans le but d'identifier
 ceux qui s'avereraient suffisamment prometteurs pour faire
 l'objet d'investigations ulterieures. L'analyse de ces plans
 peut etre consideree comme l'analyse d'une serie de
 tests qui se poursuivent jusqu'a ce que soit identified un
 traitement prometteur. Plus realiste, cette formulation accroit
 cependant, et de facon non negligeable, la complexity
 calculatoire du problem. Dans cet article, nous montrons
 que ces nouveaux plans experimentaux, ou l'on contr6le les
 risques d'erreur pour l'ensemble des traitements, peuvent
 aussi etre formulas comme des plans classiques ou l'on
 contr6le les risques d'erreur pour chaque traitement pris
 separement. Cette reformulation permet, lorsque l'on a
 besoin de construire un plan experimental concernant une
 serie de traitements, d'utiliser les tables publiees pour les
 plans classiques, ainsi que les logiciels correspondents. Nous
 illustrons tout ceci a partir d'une etude dans le sarcome des
 tissus mous.
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